Comparison of Anti Factor Xa Activity Among rivaroxaban , apixaban and edoxabanin on Japanese Non Valvular Atrial Fibrillation Patients With Renal Failure

Trial Profile

Comparison of Anti Factor Xa Activity Among rivaroxaban , apixaban and edoxabanin on Japanese Non Valvular Atrial Fibrillation Patients With Renal Failure

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Apixaban (Primary) ; Edoxaban (Primary) ; Rivaroxaban (Primary)
  • Indications Atrial fibrillation
  • Focus Pharmacokinetics
  • Most Recent Events

    • 28 Nov 2017 New trial record
    • 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top